Navigation Links
Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team
Date:7/19/2013

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. 

Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research Team. 

"We are excited to have Marshall join our team. He has had a distinguished career on Wall Street, and this experience coupled with his deep analytical skills make him an excellent addition to Royalty Pharma," said Pablo Legorreta, Founder and CEO of Royalty Pharma.

Dr. Urist graduated Phi Beta Kappa from Johns Hopkins University and holds a MD and PhD from Columbia University.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products. With over $10 billion in assets, Royalty Pharma owns royalty interests in 41 marketed and late stage biopharmaceutical products, including Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche's Mircera®, UCB's Cimzia®, Biogen Idec's Tecifidera® and Pharmacyclics' ibrutinib. Additional company information is available at royaltypharma.com.

Royalty Pharma | RP Management LLC
Investor Relations
+ 1 (212) 883-0200
ir@royaltypharma.com


'/>"/>
SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cowen Healthcare Royalty Partners Raises $1 Billion
2. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
3. Royalty Pharma Statement Regarding Elan Proposal
4. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
5. Royalty Pharma Statement Regarding Elan Law Suits
6. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
7. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Pharmasset Reports Fiscal Year End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading global provider ... Overall Customer Rating Award from Circuits Assembly , today announced its milestone achievement ... Canada, Mexico and China. , The EMS provider, known in the EMS industry ...
(Date:2/9/2016)... ... ... Date and time: March 1, 2016, 5:30 p.m. to ... of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The Baruch ... house for participants to learn about a new Master of Biomedical Science (MBS) ...
(Date:2/9/2016)... , ... February 09, 2016 , ... Tunnell Consulting, Inc. ... Based in Paris, he will focus on acquiring new accounts and work closely with ... , “Fred brings to our European clients more than 15 years of ...
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):